Indoco Remedies Ltd
Indoco Remedies Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The company aims to grow from INR1,500 crores (last year) to around INR3,500 crores over the next 3 years. Indoco Remedies targets INR3,500 crores revenue in 3 years (around FY '28), down from an earlier INR5,000 crore target for FY '27 due to recent setbacks.
From Indoco Remedies Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- The company aims to grow from INR1,500 crores (last year) to around INR3,500 crores over the next 3 years.
- India business growth will focus on metros with new product launches and better returns, while supporting OTC investments.
- Europe business expects double-digit growth going forward, targeting a return to INR300+ crores run-rate by next year.
- U.S. solid oral portfolio is expected to grow steadily despite regulatory challenges, driven by vertically integrated products.
- OTC business under Warren Remedies will remain a key investment area with brand building, expected to break even at EBITDA level by FY '27 or soon after.
- API business will support growth through expanded manufacturing capabilities at new sites.
2 more points from Indoco Remedies Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Indoco Remedies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Maintenance capex in the range of INR 50 crores to INR 70 crores annually, with a maximum of INR 150 crores over the next 3 years.
- No major further capex planned for the next few years as significant investments were made in the past 2 years, including master manufacturing plant, Goa II remediation, and Warren Remedies facilities.
- Capex mainly limited to running/maintenance capital expenditures going forward.
- Investment focus has shifted towards OTC business expansion and leveraging existing capacities.
- R&D spend to reduce from around 5% to approximately 4% of sales, focusing on efficiency and vertically integrated products rather than new heavy investments.
2 more points from Indoco Remedies Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Indoco Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the current or expected order book or pending orders for Indoco Remedies Limited.
- However, management discussed growing sales in various segments including U.S., Europe, and OTC.
- They mentioned good traction in sterile products for the U.S. market and ongoing filings and approvals.
- The company expects growth in Europe with a target of INR300 crore run rate by next year.
2 more points from Indoco Remedies Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Indoco Remedies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹476 Cr, net loss ₹24 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Indoco Remedies Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Wanbury Ltd (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q2 FY26)
42.35 crore, up 21.98% year-on-year from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q2 FY26 investor presentation — and how it ran
- Senores Pharmaceuticals Ltd (Q2 FY26)
Earnings (PAT) growth has been very strong recently (e.g., 131% Y-o-Y growth in Q2) with sustained profitability momentum. Key concall takeaways from Senores…
- Caplin Point Laboratories Ltd (Q2 FY26)
After 2 years, operating margins could improve to around 40%, if markets remain favorable. Key concall takeaways from Caplin Point Laboratories Ltd's Q2 FY26…
Arthneeti Pro · Annual
Indoco Remedies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Indoco Remedies Ltd Q2 FY26 results?
The company aims to grow from INR1,500 crores (last year) to around INR3,500 crores over the next 3 years. Indoco Remedies targets INR3,500 crores revenue in 3 years (around FY '28), down from an earlier INR5,000 crore target for FY '27 due to recent setbacks.
What is Indoco Remedies Ltd share price analysis?
Indoco Remedies Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹2,268 Cr. Investors should review the full earnings analysis for detailed insights.
Is Indoco Remedies Ltd planning capital expenditure?
Maintenance capex in the range of INR 50 crores to INR 70 crores annually, with a maximum of INR 150 crores over the next 3 years. - No major further capex planned for the next few years as significant investments were made in the past 2 years, including master manufacturing plant, Goa II remediation, and Warren Remedies facilities. - Capex mainly limited to running/maintenance capital expenditures going forward. - Investment focus has shifted towards OTC business expansion and leveraging existing capacities. - R&D spend to reduce from around 5% to approximately 4% of sales, focusing on efficiency and vertically integrated products rather than new heavy investments. - Transitioned to owning market assets in regulated markets with no large upcoming capital outlays expected for U.S.
Keep Indoco Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.